Spots Global Cancer Trial Database for inoperable
Every month we try and update this database with for inoperable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer | NCT00868491 | Head and Neck C... | docetaxel, cisp... radiotherapy cetuximab, cisp... | 18 Years - | Institute of Oncology Ljubljana | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma | NCT03585673 | Esophagus Squam... Metastatic Canc... | Docetaxel-PM Oxaliplatin | 18 Years - | Dong-A University Hospital | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Apatinib for Inoperable Advanced Chondrosarcoma | NCT04260113 | Efficacy Toxicity, Drug | Apatinib Mesyla... | - | Peking University People's Hospital | |
| Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors | NCT01755182 | Neuroendocrine ... | approved pharma... TAE | 18 Years - 80 Years | National Cancer Institute, Naples | |
| Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors | NCT02636556 | Thymoma and Thy... | concurrent chem... | 18 Years - 75 Years | Fudan University | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study | NCT01190241 | Advanced Solid ... Inoperable Metastasis | desatinib or su... | 18 Years - | Amsterdam UMC, location VUmc | |
| Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer | NCT04840758 | Multiple Primar... | Stereotactic Ab... Sintilimab | 18 Years - 75 Years | The First Affiliated Hospital of Xiamen University | |
| A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | NCT00437749 | Non-Small Cell ... | CBT-1 Placebo | 18 Years - | CBA Research | |
| Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies | NCT04729205 | Cancer Gastro-Intestin... | Promitil | 18 Years - | Lipomedix Pharmaceuticals Inc. | |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | NCT04652206 | Metastatic Panc... Locally Advance... Inoperable Dise... Localized Pancr... | SCO-101 Gemcitabine Nab paclitaxel | 18 Years - | Scandion Oncology A/S | |
| Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC | NCT02619448 | Non-small Cell ... | Carboplatin Paclitaxel 70 Gy in 20 fra... | 18 Years - | State University of New York - Upstate Medical University | |
| A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | NCT03811418 | Advanced Breast... HER2-positive B... | Trastuzumab Pertuzumab Vinorelbine Docetaxel | 18 Years - | iOMEDICO AG | |
| Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02229071 | HCC | Donafenib(200mg... Donafenib(300mg... | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer | NCT02551263 | Breast Cancer | Eribulin | 20 Years - 75 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel | NCT02051868 | Squamous Cell C... | Cisplatin 5-Fluorouracil ... Carboplatin Paclitaxel | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer | NCT02551263 | Breast Cancer | Eribulin | 20 Years - 75 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC | NCT01024829 | NSCLC | Radiotherapy | 18 Years - | The Netherlands Cancer Institute | |
| A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer | NCT01364493 | Gastric Cancer | Trastuzumab+Cap... | 18 Years - | Peking University | |
| VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | NCT01486329 | Stage IV Pancre... | VXM01 Placebo | 18 Years - | Vaximm GmbH | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma | NCT00975039 | Cholangiocarcin... | WST11 | 18 Years - | Steba Biotech S.A. | |
| VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | NCT01486329 | Stage IV Pancre... | VXM01 Placebo | 18 Years - | Vaximm GmbH | |
| Apatinib for Inoperable Advanced Chondrosarcoma | NCT04260113 | Efficacy Toxicity, Drug | Apatinib Mesyla... | - | Peking University People's Hospital | |
| Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer | NCT04840758 | Multiple Primar... | Stereotactic Ab... Sintilimab | 18 Years - 75 Years | The First Affiliated Hospital of Xiamen University | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
| Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies | NCT04729205 | Cancer Gastro-Intestin... | Promitil | 18 Years - | Lipomedix Pharmaceuticals Inc. | |
| Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC) | NCT01368848 | NSCLC | Bevacizumab Cisplatin Docetaxel | 18 Years - 70 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC | NCT01024829 | NSCLC | Radiotherapy | 18 Years - | The Netherlands Cancer Institute | |
| International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel | NCT02051868 | Squamous Cell C... | Cisplatin 5-Fluorouracil ... Carboplatin Paclitaxel | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma | NCT05833594 | Esophageal Squa... Chemoradiothera... Immunonutrition Inoperable | Whole-course Im... | 18 Years - 85 Years | Anhui Provincial Hospital | |
| Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma | NCT00975039 | Cholangiocarcin... | WST11 | 18 Years - | Steba Biotech S.A. | |
| Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System | NCT01172860 | Colorectal Canc... | EndoVe endoscop... | 18 Years - | Mercy University Hospital, Cork, Ireland | |
| A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | NCT00437749 | Non-Small Cell ... | CBT-1 Placebo | 18 Years - | CBA Research | |
| Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma | NCT00779454 | Cholangiocarcin... | Gemcitabine, Ox... Panitumumab, Ge... | 18 Years - 80 Years | Vejle Hospital | |
| The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma | NCT04860700 | Malignant Adren... Malignant Parag... Pheochromocytom... Paraganglioma, ... Paraganglioma, ... | anlotinib hydro... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | NCT04652206 | Metastatic Panc... Locally Advance... Inoperable Dise... Localized Pancr... | SCO-101 Gemcitabine Nab paclitaxel | 18 Years - | Scandion Oncology A/S | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC | NCT01024829 | NSCLC | Radiotherapy | 18 Years - | The Netherlands Cancer Institute | |
| Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02229071 | HCC | Donafenib(200mg... Donafenib(300mg... | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
